MIL62
MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with a nearly completely afucosylated N-glycans in Fc region. MIL62 shows enhanced affinity for the FcγRIIIa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) [1].
Product Specifications
UNSPSC
12352203
Target
CD20
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Shi Y, et al. Efficacy and safety of MIL62, a novel glycoengineered type II anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial. EClinicalMedicine. 2024 Jun 20;73:102702.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
129139-PE 100 µL
LMO1 (Rhombotin-1, Cysteine-rich Protein TTG-1, LIM Domain Only Protein 1, LMO-1, T-cell Translocation Protein 1, RBTN1, RHOM1, TTG1, MGC116692) (PE)
Ask
View Details QP10207-ec-2ug 2ug
Recombinant Human CXCL3/ GRO gamma Protein, Untagged, E.coli-2ug
Ask
View Details